The bearish case for Eli Lilly And Co LLY's stock is based on multiple concerns, but the stock's decline since the beginning of the year implies a better risk-to-reward profile, according to BMO Capital Markets. The Analyst BMO's Alex Arfaei upgraded Eli Lilly from Underperform to Market Perform and lifted the price target from $74 to $79. SourceA bit f upside potential still holds, but it may weaken soon. $LLY, Eli Lilly and Company / D